Antiphospholipid syndrome

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Antiphospholipid antibodies (aPL) are autoantibodies directed against negatively charged phospholipid/plasma proteins. The most common plasma protein target is beta 2 glycoprotein I. The three most im-portant antiphospholipid antibodies are the lupus anti-coagulant, anticardiolipin, and anti-beta 2 glycoprotein I. Antiphospholipid syndrome (APS) is one of the most common acquired causes of hypercoagulability. Fifty percent of APS patients have systemic lupus erythe-matosus (SLE). APS presents in two major ways: thrombosis (venous or arterial) and pregnancy loss. Thrombocytopenia, present in about 20% of cases, can be an important clue.

Original languageEnglish (US)
Title of host publicationPrimer on the Rheumatic Diseases
Subtitle of host publicationThirteenth Edition
PublisherSpringer New York
Pages339-342
Number of pages4
ISBN (Print)9780387356648
DOIs
StatePublished - Dec 1 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Antiphospholipid syndrome'. Together they form a unique fingerprint.

  • Cite this

    Petri, M. (2008). Antiphospholipid syndrome. In Primer on the Rheumatic Diseases: Thirteenth Edition (pp. 339-342). Springer New York. https://doi.org/10.1007/978-0-387-68566-3_16